A Survey of Potentially Modifiable Patient-Level Factors Associated with Self-Report and Objectively Measured Adherence to Adjuvant Endocrine Therapies After Breast Cancer

References

• World Health Organization. Breast cancer. World Health Organization; 2020. Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/. Accessed October 10, 2020.
   Google Scholar
• Statistics Advisory Committee. Canadian cancer statistics. Toronto: Canadian Cancer Society; 2019. Available from: https://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2019-EN.pdf?la=en. Accessed October 10, 2020.
   Google Scholar
• American Cancer Society. Breast cancer hormone receptor status; 2020. Available from: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-hormone-receptor-status.html. Accessed July 31, 2020.
   Google Scholar
• Burstein HJ, Lacchetti C, Anderson H. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–438. doi:10.1200/JCO.18.01160
   PubMed Web of Science ®Google Scholar
• Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2018;9(1):45–53.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–784. doi:10.1016/S0140-6736(11)60993-8
   PubMed Web of Science ®Google Scholar
• Moon Z, Moss-Morris R, Hunter MS, Carlisle S, Hughes LD. Barriers and facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a systematic review. Patient Pref Adher. 2017;11:305. doi:10.2147/PPA.S126651
   PubMed Web of Science ®Google Scholar
• Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Br Can Res Treat. 2011;126(2):529–537. doi:10.1007/s10549-010-1132-4
   PubMed Web of Science ®Google Scholar
• Ekinci E, Nathoo S, Korattyil T, et al. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Can Survivorship. 2018;12(3):348–356. doi:10.1007/s11764-017-0674-4
   PubMed Web of Science ®Google Scholar
• Hurtado-de-mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB. Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review. Clin Breast Can. 2016;16(4):247–255. doi:10.1016/j.clbc.2016.03.006
   PubMed Web of Science ®Google Scholar
• Czajkowski SM, Powell LH, Adler N, et al. From ideas to efficacy: the ORBIT model for developing behavioral treatments for chronic diseases. Health Psych. 2015;34(10):971–982. doi:10.1037/hea0000161
   PubMed Web of Science ®Google Scholar
• Sawesi S, Carpenter JS, Jones J. Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review. Clin J Onc Nurs. 2014;18(3). doi:10.1188/14.CJON.E50-E57
   Google Scholar
• Lambert LK, Balneaves LG, Howard AF, Gotay CC. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. Br Can Res Treat. 2018;167(3):615–633. doi:10.1007/s10549-017-4561-5
   Web of Science ®Google Scholar
• Van Liew JR, Christensen AJ, de Moor JS. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Can Survivorship. 2014;8(3):521–531. doi:10.1007/s11764-014-0374-2
   Web of Science ®Google Scholar
• Toivonen KI, Williamson TM, Walker LM, Carlson LE, Campbell TS. Potentially modifiable factors associated with adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review. Cancers. 2021;13:107. doi:10.3390/cancers13010107
   Web of Science ®Google Scholar
• Brett J, Boulton M, Fenlon D, et al. Adjuvant endocrine therapy after breast cancer: a qualitative study of factors associated with adherence. Patient Pref Adher. 2018;12:291. doi:10.2147/PPA.S145784
   PubMed Web of Science ®Google Scholar
• Lambert LK, Balneaves LG, Howard AF, Chia SK, Gotay CC. Understanding adjuvant endocrine therapy persistence in breast cancer survivors. BMC Cancer. 2018;18(1):732. doi:10.1186/s12885-018-4644-7
   Web of Science ®Google Scholar
• AlOmeir O, Patel N, Donyai P. Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Supp Care Cancer. 2020;28:5075–5084. doi:10.1007/s00520-020-05585-9
   Web of Science ®Google Scholar
• Lumachi F, Brunello A, Maruzzo M, Basso U, Mm basso S. Treatment of estrogen receptor-positive breast cancer. Current Med Chem. 2013;20(5):596–604. doi:10.2174/092986713804999303
   PubMed Web of Science ®Google Scholar
• Perez EA. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 2007;18(supplement 8):viii26–viii35. doi:10.1093/annonc/mdm263
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. J Am Med Assoc. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Kini V, Ho PM. Interventions to improve medication adherence: a review. J Am Med Assoc. 2018;320(23):2461–2473. doi:10.1001/jama.2018.19271
   PubMed Web of Science ®Google Scholar
• Font R, Espinas JA, Gil-Gil M, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain. Br J Cancer. 2012;107(8):1249–1256. doi:10.1038/bjc.2012.389
   Web of Science ®Google Scholar
• Ziller V, Kalder M, Albert US, et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol. 2009;20(3):431–436. doi:10.1093/annonc/mdn646
   PubMed Web of Science ®Google Scholar
• Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schiz Res. 2000;42(3):241–247. doi:10.1016/S0920-9964(99)00130-9
   PubMed Web of Science ®Google Scholar
• Spoelstra SL, Given CW, Sikorskii A, et al. Feasibility of a text messaging intervention to promote self-management for patients prescribed oral anticancer agents. Onc Nurs Forum. 2015;42(6):647–657. doi:10.1188/15.ONF.647-657
   Web of Science ®Google Scholar
• Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36–44. doi:10.1345/aph.1K671
   PubMed Web of Science ®Google Scholar
• Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Measurement. 2007;15(3):203–219. doi:10.1891/106137407783095757
   PubMedGoogle Scholar
• Kimmick G, Edmond SN, Bosworth HB, et al. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast. 2015;24(5):630–636. doi:10.1016/j.breast.2015.06.010
   PubMed Web of Science ®Google Scholar
• Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. Diabetes Care. 1998;21(10):1644–1651. doi:10.2337/diacare.21.10.1644
   PubMed Web of Science ®Google Scholar
• Levesque CS, Williams GC, Elliot D, Pickering MA, Bodenhamer B, Finley PJ. Validating the theoretical structure of the Treatment Self-Regulation Questionnaire (TSRQ) across three different health behaviors. Health Ed Res. 2007;2(5):691–702.
   Web of Science ®Google Scholar
• Müller S, Kohlmann T, Wilke T. Validation of the adherence barriers questionnaire–an instrument for identifying potential risk factors associated with medication-related non-adherence. BMC Health Serv Res. 2015;15(1):153. doi:10.1186/s12913-015-0809-0
   Web of Science ®Google Scholar
• Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994;10(2):77–84. doi:10.1016/S0749-3797(18)30622-6
   PubMed Web of Science ®Google Scholar
• Hann D, Winter K, Jacobsen P. Measurement of depressive symptoms in cancer patients: evaluation of the Center for Epidemiological Studies Depression Scale (CES-D). J Psychosomatic Res. 1999;46(5):437–443. doi:10.1016/S0022-3999(99)00004-5
   PubMed Web of Science ®Google Scholar
• Williams GC, Grow VM, Freedman ZR, Ryan RM, Deci EL. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psych. 1996;70(1):115. doi:10.1037/0022-3514.70.1.115
   PubMed Web of Science ®Google Scholar
• Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psych. 1998;17(3):269. doi:10.1037/0278-6133.17.3.269
   PubMed Web of Science ®Google Scholar
• Shumway D, Griffith KA, Jagsi R, Gabram SG, Williams GC, Resnicow K. Psychometric properties of a brief measure of autonomy support in breast cancer patients. BMC Med Inform Dec Making. 2015;15(1):1–8.
   Google Scholar
• Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis. 2nd ed. New York: The Guilford Press; 2018.
   Google Scholar
• Ayres LR, de Oliveira Baldoni A, de Sá Borges AP, Pereira LRL. Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer. Int J Clin Pharm. 2014;36(1):45–54. doi:10.1007/s11096-013-9833-5
   Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352. doi:10.1016/S0140-6736(15)61074-1
   PubMed Web of Science ®Google Scholar
• Severeijns R, Vlaeyen JW, van den Hout MA, Weber WE. Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain. 2001;17(2):165–172. doi:10.1097/00002508-200106000-00009
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sestak I, Cella D, Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143–1148. doi:10.1016/S1470-2045(08)70259-6
   PubMed Web of Science ®Google Scholar
• Fontein DB, Seynaeve C, Hadji P, et al. Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol. 2013;31(18):2257–2264. doi:10.1200/JCO.2012.45.3068
   PubMed Web of Science ®Google Scholar
• Huober J, Cole BF, Rabaglio M, et al. Symptoms of endocrine treatment and outcome in the BIG 1-98 study. Breast Cancer Res Treat. 2014;143(1):159–169. doi:10.1007/s10549-013-2792-7
   PubMed Web of Science ®Google Scholar
• Longo CJ, Fitch MI, Loree JM, et al. Patient and family financial burden associated with cancer treatment in Canada: a national study. Supp Care Can. 2021;29:3377–3386. doi:10.1007/s00520-020-05907-x
   Web of Science ®Google Scholar
• Lee HS, Lee JY, Ah YM, et al. Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. Oncology. 2014;86(5–6):340–349. doi:10.1159/000360702
   PubMed Web of Science ®Google Scholar
• Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8(6):e149–e157. doi:10.1200/JOP.2012.000543
   PubMedGoogle Scholar
• Yi M, Hwang E. Pain and menopause symptoms of breast cancer patients with adjuvant hormonal therapy in Korea: secondary analysis. Asia Pac J Onc Nurs. 2018;5(3):262. doi:10.4103/apjon.apjon_45_17
   Web of Science ®Google Scholar
• Franzoi MA, Agostinetto E, Perachino M, et al. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021;22(7):e303–e313. doi:10.1016/S1470-2045(20)30666-5
   PubMed Web of Science ®Google Scholar
• Nafradi L, Nakamoto K, Schulz PJ, Asnani MR. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS One. 2017;12(10):e0186458. doi:10.1371/journal.pone.0186458
   PubMed Web of Science ®Google Scholar
• Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psych Rev. 1977;84:191–215. doi:10.1037/0033-295X.84.2.191
   PubMed Web of Science ®Google Scholar
• Sheeran P, Maki A, Montanaro E, et al. The impact of changing attitudes, norms, and self-efficacy on health-related intentions and behavior: a meta-analysis. Health Psych. 2016;35(11):1178. doi:10.1037/hea0000387
   PubMed Web of Science ®Google Scholar
• Hershman DL, Kushi LH, Hillyer GC, et al. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Br Can Res Treat. 2016;157(1):133–143. doi:10.1007/s10549-016-3788-x
   PubMed Web of Science ®Google Scholar
• Bright EE, Petrie KJ, Partridge AH, Stanton AL. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. Br Can Res Treat. 2016;158(2):243–251. doi:10.1007/s10549-016-3871-3
   PubMed Web of Science ®Google Scholar
• Chan AHY, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: a measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharm. 2020;86:1281–1288. doi:10.1111/bcp.14193
   PubMed Web of Science ®Google Scholar
• Stanton AL, Bernaards CA, Ganz PA. The BCPT symptom scales: a measure of physical symptoms for women diagnosed with or at risk for breast cancer. J Natl Cancer Inst. 2005;97(6):448–456. doi:10.1093/jnci/dji069
   PubMedGoogle Scholar